Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04940299
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:17.583028+00:00
Published At
2026-03-06T00:00:00+00:00
Record Updated At
2026-03-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Bladder Carcinoma", "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Renal Pelvis Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Malignant Solid Neoplasm", "Metastatic Bladder Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v6", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-06"
protocolSection.identificationModule.nctId
"NCT04940299"
protocolSection.identificationModule.officialTitle
"A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Clinical Stage III Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Locally Advanced Bladder Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Renal Pelvis Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Renal Pelvis Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Ureter Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Urethral Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Metastatic Bladder Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)
  • Metastatic Renal Pelvis Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Ureter Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Urethral Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Urethral Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage III Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Bladder Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Renal Pelvis Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Ureter Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Urethral Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Bladder Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Bladder Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Bladder Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Lung Cancer AJCC v6 (protocolSection.conditionsModule.conditions)
  • Stage IV Renal Pelvis Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Ureter Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Urethral Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVA Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVB Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Unresectable Melanoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.